145 related articles for article (PubMed ID: 23805447)
1. [Gene expression analysis and its clinical use in breast tumors].
Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
[No Abstract] [Full Text] [Related]
2. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
Bershteĭn LM
Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
[No Abstract] [Full Text] [Related]
3. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
Ganesan S; Karantza V; Oza J; Toppmeyer D
Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
[TBL] [Abstract][Full Text] [Related]
5. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.
Giatromanolaki A; Koukourakis MI; Simopoulos C; Polychronidis A; Gatter KC; Harris AL; Sivridis E
Clin Cancer Res; 2004 Dec; 10(23):7972-7. PubMed ID: 15585632
[TBL] [Abstract][Full Text] [Related]
6. Search for new treatments intensifies for triple-negative breast cancer.
Brower V
J Natl Cancer Inst; 2009 Nov; 101(22):1536-7. PubMed ID: 19880812
[No Abstract] [Full Text] [Related]
7. [Basal subtype of breast cancer--a unit of specific characteristics of immunophenotyping?].
Niemiec J; Ryś J
Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s36-44. PubMed ID: 22693732
[No Abstract] [Full Text] [Related]
8. HER-2 protein overexpressing breast cancer without gene amplification shows higher hormone receptor expression than HER-2 protein overexpressing breast cancer with gene amplification.
Koo JS; Jung W; Yang WI
Int J Surg Pathol; 2011 Aug; 19(4):425-32. PubMed ID: 19666946
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
10. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
11. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
13. [Modern pathologic diagnostics in breast cancer].
Szoke J; Udvarhelyi N
Orv Hetil; 2012 Jan; 153(1):22-30. PubMed ID: 22204831
[TBL] [Abstract][Full Text] [Related]
14. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
17. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
18. Receptor-based predictors of response in breast cancer.
McGovern UB; Stebbing J
Future Oncol; 2009 Apr; 5(3):283-6. PubMed ID: 19374534
[No Abstract] [Full Text] [Related]
19. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: what the radiologist needs to know.
Whitman GJ; Albarracin CT; Gonzalez-Angulo AM
Semin Roentgenol; 2011 Jan; 46(1):26-39. PubMed ID: 21134526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
